CV 9104

Drug Profile

CV 9104

Alternative Names: CV-9104; RNActive®-derived prostate cancer vaccine

Latest Information Update: 30 May 2016

Price : $50

At a glance

  • Originator CureVac
  • Class Cancer vaccines; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 29 Apr 2016 CureVac terminates a phase II clinical trial in Prostate cancer (first-line therapy, in intermediate or high-risk disease) in Germany (Intradermal) (EudraCT2013-004489-32)
  • 05 Mar 2014 Phase-II clinical trials in Prostate cancer (first-line therapy, in intermediate or high-risk disease) in Germany (Intradermal)
  • 16 Dec 2013 CureVac completes enrolment in the phase IIb portion of a phase I/II trial for Prostate cancer (metastatic disease; hormone refractory; first-line therapy) in the Czech Republic, France, Germany, Poland, Spain, Sweden, Switzerland, and the UK , NCT01817738)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top